Epoch Investment Partners Inc. Raises Holdings in Amphastar Pharmaceuticals, Inc. $AMPH

Key Points

• Epoch Investment Partners Inc. increased its holdings in Amphastar Pharmaceuticals, Inc. by 14.5% in the first quarter, now owning 1,261,307 shares valued at approximately $36.57 million.
• Several large investors also boosted their stakes in Amphastar, with institutional ownership now at 65.09%.
• Amphastar's stock has shown resilience, trading at $30.34 with a market capitalization of $1.41 billion, despite mixed analyst ratings and price target adjustments.

Epoch Investment Partners Inc. lifted its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 14.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,261,307 shares of the company's stock after buying an additional 160,034 shares during the quarter. Epoch Investment Partners Inc. owned approximately 2.66% of Amphastar Pharmaceuticals worth $36,565,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. TD Asset Management Inc lifted its stake in shares of Amphastar Pharmaceuticals by 20.2% in the 1st quarter. TD Asset Management Inc now owns 2,212,142 shares of the company's stock worth $64,130,000 after purchasing an additional 371,856 shares during the period. Fuller & Thaler Asset Management Inc. lifted its stake in shares of Amphastar Pharmaceuticals by 11.5% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,263,598 shares of the company's stock worth $36,632,000 after purchasing an additional 130,672 shares during the period. Boston Trust Walden Corp lifted its stake in shares of Amphastar Pharmaceuticals by 24.2% in the 1st quarter. Boston Trust Walden Corp now owns 1,215,624 shares of the company's stock worth $35,241,000 after purchasing an additional 236,704 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Amphastar Pharmaceuticals by 9.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,198,590 shares of the company's stock worth $44,503,000 after purchasing an additional 105,288 shares during the period. Finally, Northern Trust Corp lifted its stake in shares of Amphastar Pharmaceuticals by 5.1% in the 4th quarter. Northern Trust Corp now owns 613,170 shares of the company's stock worth $22,767,000 after purchasing an additional 29,808 shares during the period. 65.09% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms recently issued reports on AMPH. Wells Fargo & Company reduced their target price on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a report on Thursday, May 8th. Needham & Company LLC raised shares of Amphastar Pharmaceuticals from a "hold" rating to a "buy" rating and set a $36.00 target price for the company in a report on Tuesday, August 12th. Piper Sandler reduced their target price on shares of Amphastar Pharmaceuticals from $30.00 to $25.00 and set a "neutral" rating for the company in a report on Friday, August 8th. JPMorgan Chase & Co. reissued a "neutral" rating and issued a $30.00 target price (down from $45.00) on shares of Amphastar Pharmaceuticals in a report on Monday, May 12th. Finally, Bank of America increased their target price on shares of Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the stock a "neutral" rating in a report on Tuesday. Two analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $31.60.

Amphastar Pharmaceuticals Price Performance

Shares of AMPH stock traded up $0.36 on Friday, reaching $30.62. The company's stock had a trading volume of 290,925 shares, compared to its average volume of 638,844. The stock's fifty day simple moving average is $24.60 and its 200-day simple moving average is $25.79. Amphastar Pharmaceuticals, Inc. has a 1 year low of $20.39 and a 1 year high of $53.96. The company has a current ratio of 3.29, a quick ratio of 2.21 and a debt-to-equity ratio of 0.80. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of 11.47 and a beta of 0.76.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.